Decrease of functional activated T and B cells and treatment of glomerulonephitis in lupus-prone mice using a natural flavonoid astilbin

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Guo, Lele ^a   Liu, Wen ^a   Lu, Tingting ^a   Guo, Wenjie ^a   Gao, Jian ^a   Luo, Qiong ^a   Wu, Xuefeng ^a   Sun, Yang ^a   Wu, Xudong ^a   Shen, Yan ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ASTILBIN; B CELL ACTIVATING FACTOR; B7 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; FLAVONOID; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; L SELECTIN; SYNDECAN 1; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; CYTOKINE; FLAVONOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG DOSE COMPARISON; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHADENOPATHY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PLASMA CELL; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; COMPLICATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; T LYMPHOCYTE;

MUS;

ANIMALS; B-LYMPHOCYTES; CYTOKINES; FEMALE; FLAVONOLS; GLOMERULONEPHRITIS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES;

EID: 84928905844     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124002     Document Type: Article

References (36)

1. Robak E, Robak T. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity. Curr Med Chem. 2012; 19(3):438-53. PMID: 22335517.
2. Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010; 16(2):47-57. doi:10.1016/j.molmed.2009.12.005 PMID: 20138006.
3. Nagy G, Koncz A, Perl A. T- And B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol. 2005; 25(2):123-40. PMID: 15952933.
4. Grech P, Khamashta M. Targeted therapies in systemic lupus erythematosus. Lupus. 2013; 22 (10):978-86. doi:10.1177/0961203313499417 PMID: 23963429.
5. Mok CC. Emerging biological therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs. 2014; 19(2):303-22. doi:10.1517/14728214.2014.894018 PMID: 24588398.
6. Mok CC. Update on B-cell targeted therapies for systemic lupus erythematosus. Expert Opin Biol Ther. 2014; 14(6):773-88. doi:10.1517/14712598.2014.895810 PMID: 24588110.
7. Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol: JASN. 2010; 21(12):2028-35. doi:10.1681/ASN.2010050472 PMID: 21051743.
8. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: An update on clinical trial data. Drugs. 2010; 70(5):529-40. doi:10.2165/11535420-000000000-00000 PMID: 20297867.
9. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti- CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003; 48(3):719-27. PMID: 12632425.
10. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2010; 62(10):3077-87. doi:10.1002/art.27601 PMID: 20533545.
11. Chen T, Li J, Cao J, Xu Q, Komatsu K, Namba T. A new flavanone isolated from rhizoma smilacis glabrae and the structural requirements of its derivatives for preventing immunological hepatocyte damage. Planta Med. 1999; 65(1):56-9. PMID: 10083847.
12. Chen TH, Liu JC, Chang JJ, Tsai MF, Hsieh MH, Chan P. The in vitro inhibitory effect of flavonoid astilbin on 3-hydroxy-3-methylglutaryl coenzyme A reductase on Vero cells. Zhonghua Yi Xue Za Zhi (Taipei). 2001; 64(7):382-7. PMID: 11584575.
13. Haraguchi H, Mochida Y, Sakai S, Masuda H, Tamura Y, Mizutani K, et al. Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis. Biosci Biotechnol Biochem. 1996; 60(6):945- 8. PMID: 8695910.
14. Fei M, Wu X, Xu Q. Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin A. J Allergy Clin Immunol. 2005; 116(6):1350-6. PMID: 16337470.
15. Wang J, Zhao Y, Xu Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-alpha production and T lymphocytes adhesion. J Pharm Pharmacol. 2004; 56(4):495-502. PMID: 15104095.
16. Xu Q, Wu F, Cao J, Chen T, Jiang J, Saiki I, et al. Astilbin selectively induces dysfunction of liver-infiltrating cells-novel protection from liver damage. Eur J Pharmacol. 1999; 377(1):93-100. PMID: 10448932.
17. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin- Activated Jurkat cells. Pharmacol Res. 2001; 44(2):135-9. PMID: 11516264.
18. Yi HW, Lu XM, Fang F, Wang J, Xu Q. Astilbin inhibits the adhesion of T lymphocytes via decreasing TNF-alpha and its associated MMP-9 activity and CD44 expression. Int Immunopharmacol. 2008; 8 (10):1467-74. doi:10.1016/j.intimp.2008.06.006 PMID: 18606251.
19. Ding Y, Liang Y, Deng B, Qiao A, Wu K, Xiao W, et al. Induction of TGF-beta and IL-10 production in dendritic cells using astilbin to inhibit dextran sulfate sodium-induced colitis. Biochem Biophys Res Commun. 2014; 446(2):529-34. doi:10.1016/j.bbrc.2014.02.136 PMID: 24613838.
20. Zou S, Shen X, Tang Y, Fu Z, Zheng Q, Wang Q. Astilbin suppresses acute heart allograft rejection by inhibiting maturation and function of dendritic cells in mice. Transplant Proc. 2010; 42(9):3798-802. doi:10.1016/j.transproceed.2010.06.031 PMID: 21094859.
21. Cai Y, Chen T, Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm Res. 2003; 52(8):334-40. PMID: 14504671.
22. Guo J, Qian F, Li J, Xu Q, Chen T. Identification of a new metabolite of astilbin, 3'-O-methylastilbin, and its immunosuppressive activity against contact dermatitis. Clin Chem. 2007; 53(3):465-71. PMID: 17272490.
23. Tang J, Guo J, Fan J, Qian C, Tao F, Zhou X, et al. Metabolite profiling of astilbin in rat sera using UPLC/MS(E) and impact of its metabolites on immunosuppressive activity. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 929:56-62. doi:10.1016/j.jchromb.2013.04.018 PMID: 23665891.
24. Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol. 2011; 187(7):3840-53. doi:10.4049/jimmunol.1101228 PMID: 21880982.
25. Hou LF, He SJ, Li X, Yang Y, He PL, Zhou Y, et al. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum. 2011; 63(8):2445-55. doi:10.1002/art.30392 PMID: 21484768.
26. Mosca M, van Vollenhoven R. New drugs in systemic lupus erythematosus: when to start and when to stop. Clin Exp Rheumatol. 2013; 31(4 Suppl 78):82-5. PMID: 24129144.
27. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol. 1985; 37:269-390. PMID: 3890479.
28. Izawa T, Kondo T, Kurosawa M, Oura R, Matsumoto K, Tanaka E, et al. Fas-independent T-cell apoptosis by dendritic cells controls autoimmune arthritis in MRL/lpr mice. PloS one. 2012; 7(12):e48798. doi:10.1371/journal.pone.0048798 PMID: 23300516.
29. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. PMID: 17587156.
30. Ichinose K, Juang YT, Crispin JC, Kis-Toth K, Tsokos GC. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum. 2011; 63(2):523-9. doi:10.1002/art.30085 PMID: 20954187.
31. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013; 15(4):R97. doi:10.1186/ar4277 PMID: 23968496.
32. Winter O, Moser K, Mohr E, Zotos D, Kaminski H, Szyska M, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood. 2010; 116(11):1867-75. doi:10.1182/blood-2009-12-259457 PMID: 20538807.
33. Giltiay NV, Lu Y, Cullen JL, Jorgensen TN, Shlomchik MJ, Li X. Spontaneous loss of tolerance of autoreactive B cells in Act1-deficient rheumatoid factor transgenic mice. J Immunol. 2013; 191(5):2155-63. doi:10.4049/jimmunol.1300152 PMID: 23904159.
34. Davidson A. The rationale for BAFF inhibition in systemic lupus erythematosus. Curr Rheumatol Rep. 2012; 14(4):295-302. doi:10.1007/s11926-012-0258-2 PMID: 22535567.
35. Roth R, Nakamura T, Mamula MJ. B7 costimulation and autoantigen specificity enable B cells to activate autoreactive T cells. J Immunol. 1996; 157(7):2924-31. PMID: 8816398.
36. Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus. J Immunol. 2000; 165(6):3436-43. PMID: 10975864.